Arbutus Biopharma Corp

  • Moat Score
  • Safety Score
  • Market Cap $691.84M
  • PE -9
  • Debt $0.00
  • Cash $31.85M
  • EV $659.99M
  • FCF -$71.92M

Earnings

loading chart...

Sales & Net Margins

loading chart...
Earnings-$76.70M
EBIT-$81.24M
ROE-72%
ROA-58%
FCF-$71.92M
Equity$106.89M
Growth Stability1
PE-9.02
PB6.47
P/FCF-9.62
P/S102.62
Price/Cash0.05
Debt/Equity0
Debt/FCF-0
Net Margins-1K%
Op. Margins-1K%
Sales Growth YoY-71%
Sales Growth QoQ-22%
Sales CAGR13%
Equity CAGR-13%
Earnings Growth YoY-2%
Earnings Growth QoQ-0%
Sales CAGR 5Y25%
Equity CAGR 5Y10%
Earnings CAGR 3Y-29%
Sales CAGR 3Y-29%
Equity CAGR 3Y-15%
Market Cap$691.84M
Revenue$6.74M
Assets$140.44M
Total Debt$0.00
Cash$31.85M
Shares Outstanding184.24M
EV659.99M
Moat Score1%
Safety Score65%
Working Capital113.85M
Current Ratio7.02
Shares Growth 3y15%
Equity Growth QoQ-13%
Equity Growth YoY-10%

Assets & ROA

loading chart...

Stockholders Equity & ROE

loading chart...
Arbutus Biopharma Corp is a biopharmaceutical company. The company discovers, develops, and commercializes cures for patients suffering from Hepatitis B infection. It is focused on developing a portfolio of drug candidates with multiple mechanisms of action and is also involved in licensing Lipid nanoparticle technology.

SEC Filings

Direct access to Arbutus Biopharma Corp (ABUS) Annual Reports (10K) and Quarterly Reports (10Q) from the SEC website.

  • 2024
    • 10-Q Sep 30
    • 10-Q Jun 30
    • 10-Q Mar 31
  • 2023
    • 10-K Dec 31
    • 10-Q Sep 30
    • 10-Q Jun 30
    • 10-Q Mar 31
  • 2022
    • 10-K Dec 31
    • 10-Q Sep 30
    • 10-Q Jun 30
    • 10-Q Mar 31

Sector Comparison

How does Arbutus Biopharma Corp compare to its competitors?

Loading chart...

Peter Lynch's Chart

This chart shows the current pricing of Arbutus Biopharma Corp compared to its past. The addition of the earnings trend line provides further insights into the company's earnings power.

loading chart...

Arbutus Biopharma Corp Discounted Cash Flow

Fully customizable DCF calculator online for Arbutus Biopharma Corp.

= -$719M
012345678910TV
fcf-$72M-$72M-$72M-$72M-$72M-$72M-$72M-$72M-$72M-$72M-$72M-$719M
DCF-$65M-$59M-$54M-$49M-$45M-$41M-$37M-$34M-$31M-$28M-$277M
Value-$719M

Competitiveness and MOAT

High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

Years12/201412/201512/201612/201712/201812/201912/202012/202112/202212/2023TTM
Net Margins-260%-252%-26K%-797%-1K%-3K%-1K%-804%-178%-402%-1K%
ROA--11%-177%-46%-27%-137%-42%-36%-32%-50%-58%
ROE--11%-189%-47%-34%-227%-74%-52%-51%-69%-72%

Safety and Stability

Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

Years12/201412/201512/201612/201712/201812/201912/202012/202112/202212/2023TTM
Debt over FCF--------0-0-0-0
Debt over Equity-------0000
Growth Stability----------1

Growth

Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

Years12/201412/201512/201612/201712/201812/201912/202012/202112/202212/2023CAGR 5Y
Revenue YoY growth-66%-94%618%-44%1%15%59%255%-54%25%
Earnings YoY growth-61%513%-78%-21%146%-54%16%-21%5%-
Equity YoY growth-522%-63%-10%10%-64%40%66%-19%-23%10%
FCF YoY growth-323%8%-10%23%4%-28%32%-48%142%-